Drug intelligence / Profile preview

NEXI-100

Development stage: Preclinical
Lead developer: NexImmune
Modality: Nanoparticles → Drug Delivery Systems
Administration: Injectable

Overview

NEXI-100 is an investigational oncology therapeutic candidate developed by NexImmune, utilizing the proprietary Artificial Immune Modulation (AIM) nanoparticle technology platform. Designed as an "off-the-shelf" injectable, these nanoparticles function as synthetic dendritic cells that engage, activate, and expand endogenous multi-antigen-specific T cells. The goal is to direct a potent, persistent, and precise T cell-mediated immune response against hematologic malignancies and solid tumors while minimizing off-target toxicities. As of 2023, NEXI-100 is in the discovery and preclinical stages of development.

Other names: NEXI 100NEXI100NEXI-100NEXI-100 seriesNEXI100 seriesNEXI 100 series

Targets

CD28 (Cluster of Differentiation 28)γδ TCR (T-cell receptor)

Beyond the preview

Go deeper on NEXI-100.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NEXI-100.

Explore the full profile